This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Ray, J. A Articles by Renaudin, C. Search for Related Content Social Bookmarking                         What's this?

Long-term costs and clinical outcomes associated with metformin-glibenclamide combination tablets (Glucovance®) in patients with type 2 diabetes sub-optimally controlled by metformin: a modelling study in the French setting

CORE, Center for Outcomes Research, A Unit of IMS Health, Gewerbestrasse 25, 4123 Allschwil, Switzerland

Dominique Huet

Hopital St Michel, 33 rue Olivier De Serres, Paris 75015, France

William J Valentine

CORE, Center for Outcomes Research, A Unit of IMS Health, Gewerbestrasse 25, 4123 Allschwil, Switzerland

Andrew J Palmer

CORE, Center for Outcomes Research, A Unit of IMS Health, Gewerbestrasse 25, 4123 Allschwil, Switzerland

Nathalie Cugnardey

Medical and Regulatory Department, Merck Lipha Santé, part of Merck Serono, 37 rue Saint-Romain, 69008 Lyon, France

Corinne Renaudin

Pricing and Health Economics - Global Marketing, Merck Santé, part of Merck Serono, 37 rue Saint-Romain, 69008 Lyon, France, corinne.renaudin{at}merck.fr

Objectives

Most patients eventually become hyperglycaemic on metformin monotherapy. We modelled clinical and economic consequences for such patients of switching to a single-tablet metformin-glibenclamide combination (Glucovance®) or glibenclamide, or increasing metformin dosage.

Methods

A validated computer simulation model of diabetes projected long-term clinical and cost outcomes for the French setting, using data from a 16-week randomised controlled trial.

Results

Compared with metformin, Glucovance® 500/2.5 mg or 500/5 mg was associated with increased quality-adjusted life expectancy (0.45 and 0.27 quality-adjusted life-years [QALYs] respectively; base case analysis), reduced direct medical costs (by 3,331 and 2,026) and fewer diabetes-related complications. Compared with glibenclamide, Glucovance® 500/5 mg increased quality-adjusted life expectancy by 0.28 QALYs and reduced direct medical costs by 1,793.

Conclusions

From a third-party healthcare payer perspective in France, Glucovance® represents a dominant treatment option versus metformin or glibenclamide for patients sub-optimally controlled on metformin monotherapy.

Key Words: cost-effectiveness • glibenclamide • Glucovance® • metformin • oral antidiabetic combination therapy • type 2 diabetes.

References

• UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Clinical Guidelines Task Force, International Diabetes Federation. 2005 Global Guideline for Type 2 Diabetes. Available at www.idf.org
• Nathan DM, Buse JB, Davidson MB et al. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2006;49:1711-21.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Turner RC, Cull CA, Frighi V., Holman RR Glycaemic control with diet, sulphonylurea, metformin or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49). JAMA 1999;281:2005-12.[Abstract/Free Full Text]
• Scarpello JHB. Optimal dosing strategies for maximising the clinical response to metformin in type 2 diabetes. Br J Diabetes Vasc Dis 2001;1:28-36.[Abstract/Free Full Text]
• Marre M., Howlett H., Lehert P., Allavoine T. Improved glycaemic control with metformin-glibenclamide combined tablet therapy (Glucovance®) in Type 2 diabetic patients inadequately controlled on metformin. Diabet Med 2002;19:673-80.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Palmer AJ, Roze S., Valentine WJ et al. The CORE Diabetes Model: Projecting Long-term Clinical Outcomes, Costs and Cost-effectiveness of Interventions in Diabetes Mellitus (Types 1 and 2) to Support Clinical and Reimbursement Decision-making. Curr Med Res Opin 2004;20(8
• suppl):5-26. 8. Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Br Med J 2000;321:405-12.[Abstract/Free Full Text]
• Palmer AJ, Roze S., Valentine W. et al. P Validation of the CORE Diabetes Model against Epidemiological and Clinical Studies. Curr Med Res Opin 2004;20(suppl 1):S27-S40.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Detournay B., Cros S., Charbonnel B. et al. Managing type 2 diabetes in France: the ECODIA survey. Diabetes Metab 2000;26:363-9.[Web of Science][Medline] [Order article via Infotrieve]
• Fagnani F., Souchet T., Labed D. Incidence, management and cost of cardio-vascular and renal complications in French type 2 diabetic patients in 2001 [Abstract]. Value Health 2003;5:206.
• Montagne O., Chaix C., Harf A., Castaigne A., Durand-Zaleski I. Costs for acute myocardial infarction in a tertiary care centre and nationwide in France. Pharmacoeconomics 2000;17:603-09.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Levy P., Lechat P., Leizorovicz A., Levy E. A cost-minimization of heart failure therapy with bisoprolol in the French setting: an analysis from CIBIS trial data. Cardiac Insufficiency Bisoprolol Study. Cardiovasc Drugs Ther 1998;12:301-05.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• LePen C., Lilliu H., Keller T., Fiessinger S. The economics of TRACE. A cost-effectiveness analysis of trandolapril in postinfarction patients with left ventricular dysfunction. Pharmacoeconomics 1998;14:49-58.[Web of Science][Medline] [Order article via Infotrieve]
• Mullins CD, Sikirica M., Seneviratne V., Ahn J., Akhras KS Comparisons of hypertension-related costs from multinational clinical studies. Pharmacoeconomics 2004;22:1001-14.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Levy E., Gabriel S., Dinet J. The comparative medical costs of atherothrombotic disease in European countries. Pharmacoeconomics 2003;21:651-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Palmer AJ, Annemans L., Roze S., Lamotte M., Rodby RA, Cordonnier D. An economic evaluation of irbesartan in the treatment of patients with type 2 diabetes, hypertension and nephropathy; cost-effectiveness of Irbesartan in Diabetic Nephropathy Trial (IDNT) in the Belgian, and French settings. Nephrol Dial Transplant 2003;18:2059-66.[Abstract/Free Full Text]
• Grueger J., O'Brien B., Caro J., Everhard F. The lifetime direct medical costs of managing diabetes and its complications in France [Abstract]. Value Health 2001;4:504-05.
• Bonastre J., Le Pen C., Soubrane G., Quentel G. The burden of age-related macular degeneration: results of a cohort study in two French referral centres. Pharmacoeconomics 2003;21:181-90.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Nghiem-Buffet MH, de Pouvourville G., Renard G., Ullern M., Boureau C., Chaine G. [Cost of managing cataracts. Evaluation of traditional hospitalization and ambulatory surgery]. Presse Med 2001;30:1924-6.[Web of Science][Medline] [Order article via Infotrieve]
• Ghatnekar O., Persson U., Willis M., Odegaard K. Cost effectiveness of Becaplermin in the treatment of diabetic foot ulcers in four European countries. Pharmacoeconomics 2001;19:767-78.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Cnamts. La Classification Commune des Actes Médicaux (CCAM). 2002.
• Vidal®. L'information de référence sur le medicament, www.vidalip.net
• Tarn T., Smith M. Pharmacoeconomic guidelines around the world. ISPOR Connections 2004;10:5-15.
• Briggs AH, Wonderling DE, Mooney CZ Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Econ 1997;6:327-40.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Garber AJ, Duncan TG, Goodman AM, Mills DJ, Rohlf JL Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am J Med 1997;103:491-7.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Charpentier G., Genes N., Vaur L. et al. Control of diabetes and cardiovascular risk factors in patients with type 2 diabetes: a nationwide French survey. Diabetes Metab 2003;29:152-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Fox KM, Gerber Pharmd RA, Bolinder B., Chen J., Kumar S. Prevalence of inadequate glycemic control among patients with type 2 diabetes in the United Kingdom general practice research database: A series of retrospective analyses of data from 1998 through 2002. Clin Ther 2006;28:388-95.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Del Prato S., Felton AM, Munro N., Nesto R., Zimmet P., Zinman B. Improving glucose management: ten steps to get more patients with type 2 diabetes to glycaemic goal. Int J Clin Pract 2005;59:1345-55.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Veehof L., Stewart R., Haaijer-Ruskamp F., Jong BM The development of polypharmacy. A longitudinal study. Fam Pract 2000;17:261-7.[Abstract/Free Full Text]
• Rubin RR Adherence to pharmacologic therapy in patients with type 2 diabetes mellitus. Am J Med 2005;118 (suppl 5A):27S-34S.[Web of Science][Medline] [Order article via Infotrieve]
• Dailey G., Kim MS, Lian JF Patient compliance and persistence with anti-hyperglycaemic therapy: evaluation of a population of type 2 diabetic patients. J Int Med Res 2002;30:71-9.[Web of Science][Medline] [Order article via Infotrieve]
• Melikian C., White TJ, Vanderplas A., Derji CM, Chang E. Adherence to oral antidiabetic therapy in a managed care organisation: a comparison of monotherapy, combination therapy and fixed-dose combination therapy. Clin Ther 2002;24:460-7.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Duckworth W., Marcelli M., Padden M. et al. Improvements in glycemic control in type 2 diabetes patients switched from sulfonylurea coadministered with metformin to glyburide-metformin tablets. J Manag Care Pharm 2003;9:256-62.[Medline] [Order article via Infotrieve]
• Kahn SE, Haffner SM, Heise MA et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-43.[Abstract/Free Full Text]

The British Journal of Diabetes & Vascular Disease, Vol. 8, No. 1, 39-44 (2008)
DOI: 10.1177/14746514080080010901


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Ray, J. A Articles by Renaudin, C. Search for Related Content Social Bookmarking                         What's this?